Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies

被引：33

作者：

Becker, Richard C. ^{[1
]}

Gurbel, Paul A. ^{[2
]}

机构：

[1] Duke Univ, Sch Med, Durham, NC USA

[2] Sinai Ctr Thrombosis Res, Baltimore, MD USA

来源：

THROMBOSIS AND HAEMOSTASIS | 2010年 / 103卷 / 03期

关键词：

Platelet P2Y(12) receptor; clopidogrel; prasugrel; ticagrelor; cangrelor; ACUTE CORONARY SYNDROMES; PRASUGREL ACHIEVES GREATER; ORAL ANTIPLATELET THERAPY; ASPIRIN-TREATED PATIENTS; RED-BLOOD-CELL; MYOCARDIAL-INFARCTION; ACTIVE METABOLITE; ISCHEMIC EVENTS; CLOPIDOGREL; ADP;

D O I：

10.1160/TH09-07-0491

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The platelet P2Y(12) receptor is involved in all aspects of arterial thrombosis, including adhesion, activation, aggregation, secretion and development of a stable aggregate on which coagulation proteins can assemble and fibrin strands can mesh. Inhibition of the P2Y(12) receptor has been shown convincingly to reduce cardiovascular events among patients with acute coronary syndromes (ACS) and in patients undergoing percutaneous intervention (PCI). Current studies are exploring whether there is a threshold of platelet aggregation below which only more bleeding occurs, without a concomitant reduction in clinical events. The following review considers the potential relevance of reversible and irreversible mechanisms of P2Y(12) inhibition to bleeding risk, posing the question, "Is it not only how much but how a platelet P2Y(12) receptor is inhibited that determines the attributable safety profile?"

引用

页码：535 / 544

页数：10

共 67 条

[41] Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting [J].

Pickard, A. Simon ;

Becker, Richard C. ;

Schumock, Glen T. ;

Frye, Carla B. .

PHARMACOTHERAPY, 2008, 28 (03) :376-392

[42] Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis [J].

Purkayastha, S ;

Athanasiou, T ;

Malinovski, V ;

Tekkis, P ;

Foale, R ;

Casula, R ;

Glenville, B ;

Darzi, A .

HEART, 2006, 92 (04) :531-532

[43] Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation [J].

Sabatine, MS ;

Cannon, CP ;

Gibson, CM ;

Lopez-Sendon, JL ;

Montalescot, G ;

Theroux, P ;

Claeys, MJ ;

Cools, F ;

Hill, KA ;

Skene, AM ;

McCabe, CH ;

Braunwald, E ;

Cannon, C ;

Sabatine, M ;

McCabe, C ;

McCagg, A ;

Job, B ;

Gaudin, C ;

Thizon-de Gaulle, I ;

Blumenthal, M ;

Saini, R ;

Delaet, I ;

Townes, L ;

Anhalt, D ;

van Holder, K ;

Skene, A ;

Hill, K ;

Braunwald, E ;

Cannon, C ;

Sabatine, M ;

McCabe, C ;

Job, B ;

Gaudin, C ;

Thizon-de Gaulle, I ;

Blumenthal, M ;

Saini, R ;

Delaet, I ;

Townes, L ;

Skene, A ;

Ardissino, D ;

Aylward, P ;

Bertrand, M ;

Bode, C ;

Budaj, A ;

Claeys, M ;

Dellborg, M ;

Ferreira, R ;

Gershlick, A ;

Huber, K .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (12) :1179-1189

[44] Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics -: The PCI-CLARITY study [J].

Sabatine, MS ;

Cannon, CP ;

Gibson, CM ;

López-Sendón, JL ;

Montalescot, G ;

Theroux, P ;

Lewis, BS ;

Murphy, SA ;

McCabe, CH ;

Braunwald, E .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (10) :1224-1232

[45] Identification and biological activity of the active metabolite of clopidogrel [J].

Savi, P ;

Pereillo, JM ;

Uzabiaga, MF ;

Combalbert, J ;

Picard, C ;

Maffrand, JP ;

Pascal, M ;

Herbert, JM .

THROMBOSIS AND HAEMOSTASIS, 2000, 84 (05) :891-896

[46] Clopidogrel and ticlopidine:: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis [J].

Savi, P ;

Herbert, JM .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (02) :174-183

[47] THE BASIC PHARMACOLOGY OF TICLOPIDINE AND CLOPIDOGREL [J].

SCHROR, K .

PLATELETS, 1993, 4 (05) :252-261

[48] Platelet interactions as therapeutic targets for prevention of atherothrombosis [J].

Smid, Jan ;

Braun-Dullaeus, Ruediger ;

Gawaz, Meinrad ;

Langer, Harald F. .

FUTURE CARDIOLOGY, 2009, 5 (03) :285-296

[49] From ATP to AZD6140:: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis [J].

Springthorpe, Brian ;

Bailey, Andrew ;

Barton, Patrick ;

Birkinshaw, Timothy N. ;

Bonnert, Roger V. ;

Brown, Roger C. ;

Chapman, David ;

Dixon, John ;

Guile, Simon D. ;

Humphries, Robert G. ;

Hunt, Simon F. ;

Ince, Francis ;

Ingall, Anthony H. ;

Kirk, Ian P. ;

Leeson, Paul D. ;

Leff, Paul ;

Lewis, Richard J. ;

Martin, Barrie P. ;

McGinnity, Dermot F. ;

Mortimore, Michael P. ;

Paine, Stuart W. ;

Pairaudeau, Garry ;

Patel, Anil ;

Rigby, Aaron J. ;

Riley, Robert J. ;

Teobald, Barry J. ;

Tomlinson, Wendy ;

Webborn, Peter J. H. ;

Willis, Paul A. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (21) :6013-6018

[50] Mechanisms involved in adenosine triphosphate-induced platelet aggregation in whole blood [J].

Stafford, NP ;

Pink, AE ;

White, AE ;

Glenn, JR ;

Heptinstall, S .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (10) :1928-1933

← 1 2 3 4 5 6 7 →